COVID-19

lancet-res-med-lenzilumab-live-air-peer-review.2021.12.01.jpg

The Lancet Respiratory Medicine – Peer-Review: Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

lancet-res-med-lenzilumab-indie-expert-comm.2021.12.01.jpg

The Lancet Respiratory Medicine – Independent Expert Commentary: Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

journal-of-medical-economics-2021.10.08.jpg

Journal of Medical Economics: Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

medRxiv-early-lenzilumab-treating-COVID.2022-01.01.jpg
biorxiv.png

GM-CSF and Cytokine Storm in Coronavirus

jtm_thumb.png

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

Mayo Clinic Proceedings
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia:
A Case-Cohort Study

mcp_thumb.png

Mayo Clinic Proceedings Lenzilumab COVID-19

Case-Cohort Study